(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.33%.
Oric Pharmaceuticals's earnings in 2026 is -$140,351,000.On average, 17 Wall Street analysts forecast ORIC's earnings for 2026 to be -$160,153,719, with the lowest ORIC earnings forecast at -$166,590,549, and the highest ORIC earnings forecast at -$153,457,757. On average, 16 Wall Street analysts forecast ORIC's earnings for 2027 to be -$180,822,058, with the lowest ORIC earnings forecast at -$201,127,614, and the highest ORIC earnings forecast at -$150,192,699.
In 2028, ORIC is forecast to generate -$181,920,777 in earnings, with the lowest earnings forecast at -$212,301,370 and the highest earnings forecast at -$107,311,595.